language_icon
EN
HI

Gland Pharma Share price

GLAND

2331

109.20 (4.91%)
NSE
BSE
Last updated on 21 May, 2026 | 15:49 IST
Today's High

2370.00

Today's Low

2230.00

52 Week Low

1452.20

52 Week High

2370.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Gland Pharma Chart

Gland Pharma Share Key Metrics

Volume
10.19 L
Market Cap
38404.72 CR
LTQ@LTP
2@2331.00
ATP
2299.48
Var Margin
17.04 %
Circuit Range
1777.5-2666.1
Delivery %
32.93 %
Value
234.43 CR
ASM/GSM
No
Market Lot
1

Summary

Gland Pharma share price is ₹2331 as of 22 May, 2026. The stock Gland Pharma intraday movement has stayed between ₹2230.00 and ₹2370.00, while on a 52-week basis,Gland Pharma price 52 week high is ₹2370.00 & its 52 week low is ₹1452.20.
In terms of trading activity, Gland Pharma has recorded a volume of 1019484 shares, The Gland Pharma has a market cap of ₹164756423 CR. The stock’s Average Traded Price (ATP) stands at ₹2299.48, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 2 @ ₹2331.00.
Gland Pharma operates within a circuit range of ₹1777.50 – ₹2666.10, with a Value of ₹234.43 CR. The Delivery Percentage for the day is 32.93%. Additionally, Gland Pharma currently falls under the No framework, and trades with a market lot size of 1.

Gland Pharma Fundamentals

View More
P/E Ratio

35.61

P/B Ratio

3.53

Div. Yield

0.9

Sector P/E

71.81

Sector P/B

3.44

Sec. Div. Yield

0.55

Gland Pharma Resistance and Support

Pivot 2239.6

Resistance

First Resistance

2277.3

Second Resistance

2332.8

Third Resistance

2370.5

Support

First Support

2184.1

Second Support

2146.4

Third Support

2090.9

Gland Pharma Shareholding Pattern

View More
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

51.83%

Mutual Fund

31.78%

Insurance

1.35%

Foreign Institutional Investors

7.29%

Domestic Institutional Investors

0.23%

Retail

7.52%

Others

0%

Total Promoters
MAR '26
51.83%

Gland Pharma Corporate Actions

DateAgenda
2026-05-15Audited Results & Final Dividend
2026-01-28Quarterly Results
2025-11-03Quarterly Results
2025-08-05Quarterly Results
2025-05-20Audited Results & Final Dividend
2025-02-03Quarterly Results

Gland Pharma News

Cenexi recovery, new product launches and capacity additions power Gland Pharma outlook

Gland Pharma reported robust Q4 FY26 consolidated net profit of ₹366.7 crore, a 96.6% year-on-year increase, with revenue rising 22.3% to ₹1,742.8 crore, driven by strong performance in its injectables business and CDMO operations. The company's positive outlook is further strengthened by the recovery of its European unit Cenexi, planned new product launches, and significant capacity expansion, including a 250% increase in GLP-1 production. A final dividend of ₹20 per share for FY26 has also been proposed, with a record date of August 11, 2026.
May 21 2026 06:05:00

Gland Pharma shares gain most in nearly three years after Q4 results, brokerage upgrade

Gland Pharma reported a robust financial performance for Q4 FY26, with its consolidated net profit surging by 96.6% year-on-year to ₹366.68 crore and revenue from operations increasing by 22.3% to ₹1,742.79 crore. This strong performance, attributed to higher revenues and improved operating leverage, resulted in a significant positive reaction in the company's shares. The board also recommended a final dividend of ₹20 per share.
May 18 2026 10:05:00

Gland Pharma shares jump 11% as Q4 profit soars 97% YoY, co announces Rs 20/share final dividend

Gland Pharma reported a 97% year-on-year surge in its Q4 FY26 consolidated net profit, reaching ₹366.7 crore, primarily driven by strong growth in its CDMO business and improved operational efficiency. Following these robust results, the company also announced a final dividend of ₹20 per share.
May 18 2026 10:05:00

Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Gland Pharma has uploaded the audio recording of its Q4 FY26 earnings call, which took place on May 15, 2026, to its official website for investor access.
May 15 2026 21:05:00

Gland Pharma Ltd - 543245 - Board Fixes Record Date Of August 11, 2026 For The Final Dividend

Gland Pharma has fixed August 11, 2026, as the Record Date for its final dividend of ₹20 per equity share for FY26. Shareholders as of this date will be eligible, with payment due within 30 days after the August 25, 2026 AGM.
May 15 2026 16:05:00

Gland Pharma Ltd - 543245 - Corporate Action-Board approves Dividend

Gland Pharma Board recommended a final dividend of ₹20 per equity share for FY26. The record date is August 11, 2026, with payment due within 30 days of the AGM.
May 15 2026 16:05:00

Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Gland Pharma reported strong Q4 FY26 results with consolidated revenue increasing 22% YoY to Rs.17,428 Mn. Adjusted net profit saw a significant rise of 97% YoY to Rs.3,667 Mn, driven by robust performance across segments.
May 15 2026 16:05:00

Gland Pharma Ltd - 543245 - Board Meeting Outcome for Outcome Of Board Meeting - 15052026

Gland Pharma reported strong Q4 FY26 cons. revenue of ₹17,428 Mn, marking a 22% YoY increase, and net profit of ₹3,667 Mn, up 97% YoY. The company's board also recommended a final dividend of ₹20 per equity share for FY26.
May 15 2026 16:05:00

Gland Pharma Ltd - 543245 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

Gland Pharma shareholders passed a special resolution to reappoint Ms. Naina Lal Kidwai as an Independent Director with 94.18% votes in favour. The approval also includes her remuneration as commission on profits.
May 14 2026 18:05:00

Gland Pharma Ltd - 543245 - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

Gland Pharma shareholders passed a special resolution to reappoint Ms. Naina Lal Kidwai as an Independent Director with 94.18% votes in favour. The approval also includes her remuneration as commission on profits.
May 14 2026 18:05:00
Read More

About Gland Pharma

NSE : 1186  
BSE : 543245  
ISIN : INE068V01023  

The Company was incorporated as ‘Gland Pharma Private Limited’ a private limited company under the Companies Act 1956 on March 20 1978 and was granted the certificate of incorporation by Registrar of Companies Andhra Pradesh at Hyderabad. Subsequently the name of the Company was changed to ‘Gland Pharma Limited’ pursuant to a special resolution passed by the shareholders of the Company on December 5 1994 and a fresh certificate of incorporation dated April 25 1995 was issued by the Registrar of Companies Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act 1956.Major events and milestones of the Company :2019- Filed Dexrazoxane for Injection the first filing with the National Medical Products Administration China and received clinical waiver2018- Received ANDA approval for Enoxaparin Sodium Injection USP for the US market- Received ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% the first Ophthalmic product approval2017- Fosun Singapore acquired 74% stake in the Company2016- Obtained USFDA approval for the facilities at Jawaharlal Nehru Pharma City Visakhapatnam- Obtained USFDA approval for the manufacturing facility at Pashamylaram- Obtained USFDA approval for the facility at the Visakhapatnam Special Economic Zone2014- Obtained USFDA approval for small volume parenteral manufacturing facility at Visakhapatnam- Commissioned the Pashamylaram Unit-II manufacturing facility- Received the ‘Certificate of GMP Compliance of a Manufacturer’ from MHRA (UK) for manufacturing facility at Dundigal- Capital infusion of US$ 100 million into the Company pursuant to private equity investment aggregating to approximately US$ 200 million with KKR Floorline Investment Pte Ltd2012- Received the ‘Certificate of GMP Compliance of a Manufacturer’ from BGV Hamburg (Germany) for the manufacturing facility at Dundigal2010- Launched Heparin Sodium Injection in the US2007- Capital infusion of approximately Rs.1000 million into the Company pursuant to private equity investment aggregating to approximately Rs.1200 million with EILSF Co-Invest I LLC2004 - 2005- Launch of Enoxaparin Sodium Injection (Cutenox) in India and Rest of the world markets2003- Received USFDA approval for the manufacturing facility at Dundigal2000- Set up the in-house R&D facility at Dundigal Hyderabad1978- Incorporation of the Company by P.V.N. RajuAwards accreditations and recognitions received by the Company :2019- The Company was awarded the “Best Exporter” by the Hyderabad Customs- The Company was awarded the “Express Pharma Excellence Awards 2019” under the turnover base Rs. 500 – 2000 crore category organized by the Express Pharma and Optel Group- The Company was awarded the “Telangana Best Employer Brand Award” at the 14th Employer Branding Awards organised by the Employer Branding Institute India2018- The Company was awarded the “Top Exporter” by the Hyderabad Customs Customs and Central Excise Government of India- The Company was awarded the “Outstanding Export Performance Award” under Formulations Silver Star category by Pharmaceuticals Export Promotion Council of India2017- The Company was awarded the “Excellence in Export Performance” at the Federation of Telangana and Andhra Pradesh Chambers of Commerce and Industry instituted by Surana Group of Industries Secunderabad- The Company was awarded the “Outstanding Export Performance Award” under Formulations Fast Growing -1 category by Pharmaceuticals Export Promotion Council of India2016- The Company was awarded the “Top Exporter/Importer” by the Hyderabad Customs Commissionerate Customs and Central Excise Government of India2014- The Company was awarded the “Outstanding Exports Performance Award” under the Regional (America and Oceania) category by Pharmaceuticals Export Promotion Council of India- The Company received the BS OHSAS 18001:2007 certifying the occupational health and safety management system of the manufacturing facility at Dundigal- The Company received ISO 14001:2015 certifying the environmental management system of the manufacturing facility at Dundigal- The Company received ISO 9001:2015 certifying the quality management system of manufacturing facility at Dundigal

Read More

Gland Pharma Management

NamePosition
Sampath Kumar PallerlamudiCompany Secretary & Compliance Officer
Srinivas SaduChairman
View More

Gland Pharma FAQs

The Buying Price of Gland Pharma share is 2331 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Gland Pharma stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Gland Pharma, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Gland Pharma shares is 35.61. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Gland Pharma shares is 3.53. Useful to assess the stock's value relative to its book value.

To assess Gland Pharma’s valuation compare Sector P/E, P/B which are 71.81 & 3.44 with sector averages, along with growth rates and financial metrics.

The Market Cap of Gland Pharma is 38404.72 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Gland Pharma share price is 2370.00 & 1452.20. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Gland Pharma belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost